Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
AA

Ratings ESG MSCI

Ratings Gilead Sciences, Inc.: Strengths and Weaknesses

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
  • According to MSCI, the company's ESG score for its industry is good.
Highlights: Gilead Sciences, Inc.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
  • Historically, the company has been releasing figures that are above expectations.
Weaknesses: Gilead Sciences, Inc.
  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is highly valued given the cash flows generated by its activity.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.

Rating Financials

Gilead Sciences, Inc. SectorUnited States

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Gilead Sciences, Inc. SectorUnited States

Global Valuation

Enterprise value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Gilead Sciences, Inc. SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Gilead Sciences, Inc. SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Gilead Sciences, Inc. SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
164B
AA
898B
A
556B
BBB
372B -
AA
- -
326B
AA
287B
A
285B
AAA
280B
A
207B
A
181B
A
Average 355.64B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Equities
  3. GILD Stock
  4. Ratings Gilead Sciences, Inc.